TY  - BOOK
AU  - 
AU  - 
AU  - 
TI  - The Prevalence of Hepatitis B Treatment Naive Patients Who Are Not on Treatment, And Associated Complications Among Adults at Bugando Medical Centre, Mwanza
PY  - 2024///
CY  - Mwanza, Tanzania |
PB  - Catholic University of Health and Allied Sciences [CUHAS-Bugando] |
KW  -  
N2  - Abstract:

Background: Hepatitis B infection is a disease of global significance affecting large number of people. Chronic Hepatitis B (CHB) infection which embraces a large spectrum of the disease remains to be a serious public health problem globally with over 240 million people being affected and causing 650,000 deaths annually [1]. A seroprevalence of HBV infection in the country was reported to be 6% in the general population of Dar es Salaam [6] 

Method: The study included records of Medical out-patients’ patients with confirmed Hepatitis B infection at BMC, seen from January 2023 to June 2024, a Systemic random sampling was applied to select study participants who meet inclusion criteria, from the patient records of the hospital.

Results: The current study shows that the prevalence of the Hepatitis B treatment naive patients who are not on treatment is 208 (69.6%) among 299 of the Hepatitis B Positive patients seen at MOPD from January 2023 to June 2024, who were not in treatment related to hepatitis B were recorded to be not medically indicated for hepatitis B treatment 205(98.6%) while others as eligible for medications, prescribed but couldn’t buy 3(1.4%) respectively, of which 168 (56.2%) of patients didn’t have health insurance and all patients who didn’t receive required treatment due to eligible for medications, though couldn’t buy 3(1.4%) didn’t have health insurance 3 (100%), Hepatitis B Treatment naïve who were not in Treatment, 46 (22.1%) had complications, of which 17 (37%) with Portal hypertension, 16(34.8%) Liver cancer, 3(6.5%) Hepatorenal Syndrome, and 1 (2.2%) for Hepatic encephalopathy 

Conclusion: The study highlights a significant prevalence of Hepatitis B treatment-naive patients who are not on treatment, with 69.6% of the Hepatitis B positive patients at MOPD from January 2023 to June 2024 being untreated. The primary reason for non-treatment was the lack of medical indication, accounting for 98.6% of the cases. Other included eligible for medications, prescribed but couldn’t buy 3(1.4%), particularly among those without health insurance. The study also identified serious complications among untreated patients, including portal hypertension, liver cancer, renal complications, and hepatic encephalopathy.

ER  -